Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and LUIS E FAYAD.
Connection Strength
0.604
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
Score: 0.103
-
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66.
Score: 0.096
-
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.
Score: 0.088
-
Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res. 1999 Sep; 5(9):2491-7.
Score: 0.043
-
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
Score: 0.040
-
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018 02; 32(2):353-363.
Score: 0.037
-
Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997 May; 11(5):767-71.
Score: 0.037
-
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan; 172(1):80-8.
Score: 0.034
-
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35.
Score: 0.033
-
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8.
Score: 0.023
-
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41.
Score: 0.021
-
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302.
Score: 0.018
-
Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol. 2000 Dec; 11(12):1551-6.
Score: 0.012
-
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia. 1998 Apr; 12(4):455-62.
Score: 0.010
-
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med. 1998 Mar; 104(3):246-51.
Score: 0.010